A Phase 3 interventional study of mRNA Seasonal Flu vaccine and Comparator 1 in Influenza, Human, sponsored by GlaxoSmithKline. Recruiting at 12 sites in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies in Influenza, Human by GlaxoSmithKline — 3 open to participants now, 3 under way, 2 of them phase 3. Influenza, Human · GlaxoSmithKline.
Among the 187 studies in Influenza, Human by GlaxoSmithKline, this one is the 20th largest by planned enrollment of the 165 interventional ones that give a count, is one of 3 that started in 2026, is one of 74 in phase 3, and was the 187th registered.
2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.
Browse Influenza, Human studies →3 of the 187 studies in Influenza, Human by GlaxoSmithKline are open now, in 1 country. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 65+ · Healthy volunteers
GlaxoSmithKline · Sites in United States
Ages 65–85
By country, each count listing its studies:
Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 56 · Phase 3 74 · Phase 4 12
First in 2002; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,000 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 324 across the 165 interventional studies, 605 across the 22 observational. Of the 178 that completed or were terminated, 132 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
2 of the studies in Influenza, Human by GlaxoSmithKline that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07851246Phase 3GlaxoSmithKlineA Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age | 2027-07-09 |
| NCT07464314GlaxoSmithKlineA Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults | 2026-12-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 187 studies in Influenza, Human by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial will study an investigational seasonal influenza vaccine in adults 18 to 64 years of age. The vaccine is based on messenger ribonucleic acid, also called mRNA. The main goals of the study are to learn how well the vaccine helps the body make an immune response against influenza and what medical problems participants may have after vaccination. Researchers will also compare immune responses in adults 18 to 64 years of age from this study, with immune responses in adults 65 years of age and older from another study. Participants will receive 1 injection into the upper arm muscle and will be followed for about 6 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants of may be enrolled, if the participant:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants 18 to 64 years of age will receive a single dose of investigational mRNA Seasonal Flu vaccine on Day 1.
Biological: mRNA Seasonal Flu vaccine
Participants 18 to 64 years of age will receive a single dose of comparator 1 on Day 1.
Biological: Comparator 1
Participants 60 to 64 years of age will receive a single dose of investigational mRNA Seasonal Flu vaccine on Day 1.
Biological: mRNA Seasonal Flu vaccine
Participants 60 to 64 years of age will receive a single dose of comparator 2 on Day 1.
Biological: Comparator 2
One dose of the mRNA Flu vaccine received intramuscularly.
One dose of the comparator vaccine received intramuscularly.
One dose of the comparator vaccine received intramuscularly.
Geometric Mean Titer (GMT) of Antigen 1 Titer
Time frame: At Day 29
GMT of Antigen 2 Titer
Time frame: At Day 29
Percentage of participants with Antigen 1 seroconversion rate (SCR)
Time frame: From Day 1 to Day 29
Number of participants with solicited administration site adverse events
Time frame: Day 1 to Day 7
Number of participants with systemic adverse events
Time frame: Day 1 to Day 7
Number of participants with unsolicited adverse events
Time frame: Day 1 to Day 28
Number of participants with serious adverse events (SAEs)
Time frame: Day 1 to Day 181
Number of participants with adverse events of special interest (AESIs)
Time frame: Day 1 to Day 181
Number of Participants with any Laboratory abnormalities
Time frame: At Day 1 (pre-dose) and at Day 29 (post - dose)
GMT of Antigen 1 and Antigen 2 antibodies
Time frame: At Day 29
Percentage of Participants with Antigen 1 and Antigen 2 antibodies SCR
Time frame: Day 1 to Day 29
Geometric Mean Increase (GMI) of Antigen 1 Titer
Time frame: At Day 29 relative to baseline (Day 1)
GMI of Antigen 2 Titer
Time frame: At Day 29 relative to baseline (Day 1)
Percentage of Participants with Antigen 1 Seroprotection Rate (SPR)
Time frame: At Day 1 and Day 29
Percentage of Participants with Antigen 2 SCR
Time frame: Day 1 to Day 29
GMT of virus neutralization titers
Time frame: At Day 29
Percentage of participants with seroconversion of virus neutralization titers
Time frame: Day 1 to Day 29
GMI of virus neutralization titers
Time frame: At Day 29 relative to baseline (Day 1)
Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Jul 2027, 9 months after the start.
Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's planned 9 months is above that.
Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.